SciSparc's Innovative ASD Therapy Trial
SciSparc has launched a clinical trial for SCI-210, a novel therapy aimed at alleviating symptoms of autism spectrum disorder in children, using a unique combination of cannabidiol and Palmitoylethanolamide.
UNVEILING NEW HORIZONS IN ASD THERAPY THROUGH INNOVATIVE CLINICAL TRIALS
Addressing Hidden Evidence in Autism Research
This study highlights the significant issue of publication bias in autism research, revealing that a large portion of clinical trials remain unpublished, obscuring valuable data.
Spectrum's Autism Drug Trial Tracker
An interactive tool providing detailed information on over 200 clinical trials for autism, helping researchers and the public track progress and understand the landscape of ASD therapy development.
Challenges in Drug Development for ASD
Discusses the difficulties faced in developing effective treatments for ASD due to the complex nature of the disorder and the lack of conclusive evidence supporting the efficacy of current drugs.
Exploring New Frontiers in ASD Treatment
Details a recent trial on AB-2004, a small-molecule sequestrant showing safety and potential efficacy in treating ASD, highlighting the importance of innovative approaches in therapy development.
Phase III Study of Bumetanide for ASD
An international, randomized, double-blind, placebo-controlled study investigating the efficacy of bumetanide in treating core symptoms of autism spectrum disorders in children and adolescents.
IAMA Therapeutics' Groundbreaking Autism Trial
IAMA Therapeutics has initiated a Phase I trial for IAMA-6, targeting NKCC1-associated neuronal hyperexcitability in autism spectrum disorder and epilepsy, marking a significant step in ASD drug discovery.